Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study / G.F. Gensini; A.M. Gori; B. Di Laghi; C. Rostagno; A. Gaw; L.M. Blanco-Colio; E. De Teresa; J. Egido; C. Farsang; L.A: Leiter; P. Martineau; A. Nozza; A. Langer. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - STAMPA. - 142:(2010), pp. 257-264.

Original Citation:
Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study / G.F. Gensini; A.M. Gori; B. Di Laghi; C. Rostagno; A. Gaw; L.M. Blanco-Colio; E. De Teresa; J. Egido; C. Farsang; L.A: Leiter; P. Martineau; A. Nozza; A. Langer. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - STAMPA. - 142:(2010), pp. 257-264.

Availability:
This version is available at: 2158/393520 since: 2018-02-28T18:15:52Z

Terms of use:
Open Access
La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf)

Publisher copyright claim:
Effect of atorvastatin on circulating hsCRP concentrations: A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study

G.F. Gensini a,b, A.M. Gori a,b, B. Dilaghi a,b, C. Rostagno a,b, A. Gaw c, L.M. Blanco-Colio d, E. de Teresa e,f, J. Egidio d, C. Farsang g, L.A. Leiter h,i, P. Martineau j, A. Nozza k, A. Langer h,i,k,*
on behalf of the ACTFAST investigators

Abstract

Background: Elevated C-reactive protein (CRP) concentration is a risk factor for cardiovascular events that may add prognostic information. Statin treatment is associated with significant reductions in CRP concentrations, which appear to be unrelated to the magnitude of LDL-cholesterol reduction. We investigated the effect of atorvastatin, across its dose range, on high sensitivity (hs)CRP in subjects at high cardiovascular risk.

Methods: ACTFAST was a 12 week, prospective, multicenter, open-label trial in which high-risk subjects were assigned a starting dose of atorvastatin (10, 20, 40 or 80 mg/d) based on LDL-C and status of statin use at screening (1345 statin-free [SF] and 772 previously statin-treated [ST]).

Results: At baseline, ST subjects had significantly lower hsCRP levels than SF subjects (ST group 2.31, 95% CI 2.15, 2.48 mg/L vs. SF group 3.16, 95% CI 2.98, 3.34 mg/L, \( p < 0.05 \)). In the SF group, atorvastatin 10 to 80 mg significantly (\( p < 0.01 \)) reduced hsCRP levels in a dose dependent-manner. In ST group, additional hsCRP reductions were observed over the statin used at baseline, which were not dose-dependent. Atorvastatin significantly decreased hsCRP concentrations in subjects with or without diabetes or the metabolic syndrome. Conclusions: Atorvastatin treatment at different doses, particularly 80 mg, significantly reduced hsCRP serum concentrations. This reduction was observed in both SF and ST groups and was independent of the presence of metabolic syndrome and/or diabetes. The beneficial effect of atorvastatin was evident at 6 weeks, supporting the practice of early introduction of higher doses of atorvastatin in high-risk patients.

Keywords: Dyslipidemia; Coronary artery disease; Statins; Atorvastatin; C-reactive protein (hsCRP)
1. Introduction

Evidence has accumulated on the role of inflammation in the pathogenesis of atherosclerosis [1,2]. Atherosclerosis, formerly considered a disease of lipid accumulation, is characterized by chronic low-grade vascular inflammation [3,4].

Despite progress in the prevention and treatment of cardiovascular disease, about half of all myocardial infarctions (MI) and strokes occur in individuals with so-called “normal” LDL cholesterol (LDL-C) levels [5]. Commonly used risk algorithms, such as the Framingham Risk Score, fail to identify all at-risk individuals, thus, the need for additional risk factors to improve identification and subsequent care of subjects at higher risk for coronary heart disease (CHD).

Acute phase reactant C-reactive protein (CRP) is a circulating pentraxin that plays a crucial role in the innate immune response and provides a stable plasma biomarker for low-grade systemic inflammation [6]. Although its role as a biomarker or a mediator of atherosclerosis is still debated, CRP actively contributes to all stages of atherogenesis, including endothelial dysfunction, atherosclerotic-plaque formation, maturation, destabilization and eventual rupture [1,7–9]. A high concentration of hsCRP has been shown to be a strong independent risk factor for cardiovascular events [1,2,10–12], thus, adding prognostic information to traditional risk factors.

In addition to their effects on LDL-C, statins have anti-inflammatory properties [13,14], as shown by significant reductions in hsCRP levels that appear to be unrelated to the magnitude of LDL-C reduction [15–18]. Statins are highly effective in reducing the risk of cardiovascular events in both primary and secondary prevention, to a degree that is greater than predicted on the basis of LDL-C lowering alone. This may be related to their anti-inflammatory actions. In the Cholesterol and Recurrent Events (CARE) and Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), the magnitude of risk reduction associated with statin therapy was higher among those with elevated hsCRP levels [19,20]. Furthermore, patients who had lower hsCRP levels after statin therapy had better clinical outcomes than those with higher levels [21,22].

The main ACTFAST study investigated the benefits of selecting the starting dose of atorvastatin based on baseline LDL-C and current CAD risk status [24]. As a sub-study to ACTFAST, we investigated the effect of atorvastatin 10, 20, 40 and 80 mg on circulating concentrations of hsCRP in subjects at high cardiovascular risk, including pre-specified subgroups of subjects with the metabolic syndrome or diabetes.

2. Methods

2.1. Study design

ACTFAST was a 12 week, prospective, multicenter, open-label trial that enrolled subjects (either statin-free [SF], never previously prescribed a statin or off therapy for at least 2 months; or statin-treated [ST] at baseline) with CHD, a CHD-equivalent (defined as diabetes, peripheral vascular disease or cerebrovascular disease) or a 10 year CHD risk >20% [23]. Subjects had LDL-C ≥ 2.6 mmol/L and ≤ 5.7 mmol/L, triglycerides ≤ 6.8 mmol/L, and had to be willing to follow the NCEP III multifaceted lifestyle approach (or equivalent). The key exclusion criteria included: current use of atorvastatin or high dose (≥ 40 mg/d) statin, use of other lipid lowering therapy (eg niacin, fibrates,...) that could not be discontinued 2 months prior to enrolment, or use of strong CYP3A4 inhibitors. Subjects were also excluded if they suffered from significant hepatic or renal impairment, uncontrolled diabetes, uncontrolled hypertension, uncontrolled primary hypothyroidism, clinically relevant gastrointestinal disease, elevation of creatine kinase (CK) level, alcohol or other drug abuse, or any severe disease or surgical procedure within 3 months of screening. A complete description of inclusion and exclusion criteria has been published elsewhere [24].

Diabetes was defined according to the 2003 American Diabetes Association criteria [26] and metabolic syndrome was defined according to the 2001 National Cholesterol Education Program (NCEP)-III [23].

The institutional review board of all participating centers approved the ACTFAST study protocol and all participants provided written informed consent. This study was conducted in compliance with the Declaration of Helsinki [25].

2.2. Treatment

One week after screening, subjects were assigned to 6 weeks of open-label treatment with atorvastatin according to their baseline LDL-C level and prior statin use, followed by an additional 6 weeks of treatment, during which subjects who had not reached LDL-C targets, were titrated to the next highest dose of atorvastatin if possible [24]. SF subjects with a baseline LDL-C of 100–149 mg/dL (2.6–3.8 mmol/L), 150–159 (3.9–4.1 mmol/L), 160–169 (4.2–4.4 mmol/L) and 170–220 mg/dL (4.5–5.7 mmol/L) were assigned to 10, 20, 40 and 80 mg of atorvastatin, respectively. Based on comparative potency with other statins, a decision was made that subjects who were on statin therapy at baseline but whose LDL-C remained above target would receive double the atorvastatin dose for the same baseline LDL-C level as compared to their untreated counterparts (up to a maximum of 80 mg), without any washout period [24]. Subjects initially allocated to atorvastatin 80 mg who did not reach LDL-C targets, were continued at that dose and a more intense therapeutic lifestyle intervention (NCEP III step 2 diet or equivalent) was recommended [23].

2.3. Laboratory determinations

All assays were performed by a central laboratory (Bio-Inova Life Sciences International, Paris and Montreal offices). Fasting venous blood samples were collected at baseline, and after 6 and 12 weeks of atorvastatin treatment for the measurement of plasma lipids, routine hematology and chemistry. Direct LDL-C measurement was performed, regardless of triglyceride levels.

Serum hsCRP was assessed using a high-sensitivity, latex microparticle-enhanced immunonutribidimetric assay (Tina-Quant; Roche Diagnostics GmbH) and measured in batches. The minimum detectable concentration of hsCRP was 0.03 mg/L. Intra-assay and inter-assay coefficients of variation of hsCRP assay were 1.34% and 5.70%, respectively. A single measurement was performed at every time point.

2.4. Statistical analysis

All analyses were performed using the SAS statistical package version 8.2. P-values less than 0.05 were considered statistically significant. Due to the skewed distribution of serum hsCRP levels, log-transformed values were used in the analyses, and back transformed for data presentation, yielding geometric means and 95% confidence intervals (CI). Computed values for the absolute and percent change in hsCRP concentrations over time for each study subject were not normally distributed. Thus, after logarithmic transformation, t-test for paired data was applied to evaluate the significance of any difference in hsCRP changes over time, both overall and within each group.
Differences in demographic, clinical and laboratory characteristics between SF and ST patients were determined using t-test for unpaired data after log-transformation of the skewed variables (i.e., hsCRP) or Chi-square test for categorical data. Correlation coefficients were computed to assess any association between hsCRP levels and various parameters. Furthermore, the correlations between the change in hsCRP observed over time and the change observed for other continuous variables were calculated by using Spearman’s correlation analysis.

Data were analyzed on an intention-to-treat (ITT) and per-protocol basis, with last observation carried forward (LOCF) being used for missing data. The ITT population consisted of all subjects assigned a starting dose, who took at least one dose of study medication, and had at least one subsequent assessment. The per protocol population consisted of those ITT subjects who: completed the study as per protocol, were exempt of major protocol violations, were compliant with study treatment, had a baseline hs-CRP \( \leq 10 \) mg/L, without acute infectious or inflammatory episode or acute trauma at the time of blood sampling, and who did not use any anti-inflammatory/immuno-modulating drugs during the study.

### 3. Results

The ITT population comprised 2117 subjects (686 on 10 mg (32.4%), 773 on 20 mg (36.5%), 234 on 40 mg (11.1%) and 424 on 80 mg (20.0%). The proportions of subjects who completed the study were 94%, 95%, 94% and 90% for the 10, 20, 40 and 80 mg doses, respectively.

Participants were mainly Caucasians (93%) and male (68%), with a mean age of 63 years (Table 1). Overall, 21% were current smokers, 39% had diabetes (97.2% were type 2), and 61% had prior CHD. A lower prevalence of diabetes and higher prevalence of CHD was observed in the ST group. As expected from the dose assignment scheme based on LDL-C and statin use at baseline, the mean baseline TC and LDL-C differed significantly between the two groups (Table 1). In the ST group, baseline serum hsCRP was significantly lower than in the SF group (ST group 2.31, 95%CI 2.15, 2.48 mg/L vs. SF group 3.16, 95% CI 2.98, 3.34 mg/L). Approximately 46% of the ITT population had baseline hsCRP circulating levels of \( \geq 3 \)mg/L.

#### 3.1. Effect of atorvastatin on hsCRP concentrations

In the SF group, the mean change from baseline in hsCRP level was significant \((p<0.0001)\) for all doses (Fig. 1) (10 mg \(-20.8\%, 95\% CI -26.1\%, -15.0\%\); 20 mg \(-28.0\%, 95\% CI -36.1\%, -18.8\%\); 40 mg \(-23.1\%, 95\% CI -32.4\%, -12.4\%\); 80 mg \(-33.6\%, 95\% CI -40.0\%, -26.1\%\).

![Fig. 1. Percent change from screening in hsCRP plasma levels in statin-free subjects. ITT, intention-to-treat; PP, per protocol. All \(p<0.05\).](image)
There were significant reductions in hsCRP compared to baseline at both 6 and 12 weeks with all doses. Further decreases in hsCRP between week 6 and 12 were significant after 6 weeks with atorvastatin 20 and 80 mg doses, and after 12 weeks with all doses. Reductions in hsCRP levels were seen in the per protocol population. Reductions in hsCRP levels were significant after 6 weeks with atorvastatin 20 and 80 mg doses, and after 12 weeks with all doses. Further decreases in hsCRP between week 6 and 12 were observed with the 20 (−9.0%; 95% CI −15.0%, −2.5%, p=0.007) and 40 mg (−20.7%, 95% CI −34.7%, −3.6%, p=0.02) doses.

3.2. Effect of atorvastatin on hsCRP concentrations according to hsCRP subgroup

The ITT population was divided into two groups according to baseline hsCRP of < or ≥3 mg/L. At baseline, 52.9% of 10 mg, 40.9% of 20 mg, 40.2% of 40 mg and 48.8% of 80 mg atorvastatin treated subjects had serum hsCRP levels ≥3 mg/L.

In SF group, there were significant reductions in hsCRP levels in subjects with baseline hsCRP levels ≥3 mg/mL, but not in those with levels <3 mg/mL, with the 10 to 40 mg doses compared to baseline, and in both hsCRP subgroups with the 80 mg dose (Table 2). In ST subjects, there were significant reductions in hsCRP concentrations when baseline was ≥3 mg/L with the 20 and 80 mg doses (Table 3).

3.3. Effect of atorvastatin on hsCRP concentrations according to metabolic syndrome status

In the SF group, baseline hsCRP levels were significantly higher in subjects with documented metabolic syndrome (defined according to the National Cholesterol Education Program (NCEP)-III [23], n=674) than in those without (n=674) (3.97, 95% CI 3.67, 4.28 mg/L vs. 2.52, 95% CI 2.33, 2.72 mg/L, p<0.0001). Atorvastatin significantly decreased hsCRP levels in both subjects with and without metabolic syndrome (Fig. 3a).

In the SF group, subjects with metabolic syndrome (n=315) also had significantly higher hsCRP levels at baseline (3.0, 95% CI 2.66, 3.37 mg/L)
than those without (n=452) (1.91, 95% CI 1.75, 2.08 mg/L, p<0.0001). Just as in the SF group, atorvastatin significantly reduced hsCRP concentrations, regardless of presence or absence of metabolic syndrome (Fig. 3b).

3.4. Effect of atorvastatin on hsCRP concentrations according to diabetes status

In the SF group, baseline hsCRP concentrations were not significantly different between subjects with diabetes (defined according to the American Diabetes Association [26], n=611) or without (n=734) (3.29, 95% CI 3.02, 3.59 mg/L vs. 3.05, 95% CI 2.83, 3.28 mg/L, p=0.18). Atorvastatin significantly decreased hsCRP levels in both subjects with and without diabetes (Fig. 4a).

Similarly, in the ST group, there were no differences in baseline hsCRP levels in subjects with (n=217) (2.41, 95% CI 2.10, 2.78 mg/L) or without diabetes (n=555) (2.27, 95% CI 2.09, 2.46 mg/L, p<0.44). The mean percent change in hsCRP from baseline was similar in subjects with or without diabetes (Fig. 4b).

3.5. Correlations with baseline hsCRP levels

In the overall study population, there were low, but significant (p<0.0001) correlations between baseline hsCRP levels and body weight, BMI, waist circumference and systolic blood pressure (r=0.19, r=0.28, r=0.27, r=0.085 respectively), but not with diastolic blood pressure (p=0.14). At study end, there were no significant correlations between change in hsCRP and body weight (r=−0.023, p=0.28), BMI (r=−0.023, p=0.28), systolic and diastolic blood pressure (r=0.042 and 0.043, respectively; p=0.05 for both).

There were small, but statistically significant correlations between change in hsCRP levels and change in LDL-C (r²=0.0117, p=0.0001) or total cholesterol concentrations (r²=0.0105, p<0.0001), but none of these were considered clinically significant.

Atorvastatin was well tolerated. Detailed safety results have been reported elsewhere [24].

4. Discussion

These results demonstrate that treatment with atorvastatin across its dose range, and particularly 80 mg, can effectively reduce circulating hsCRP serum concentrations. Reductions are observed in both patients who were statin free and those who were previously treated with a statin, and are independent of the presence of metabolic syndrome and diabetes. In ST subjects, additional reductions in hsCRP were achieved over what was obtained with the prior statin. The greatest reductions in hsCRP were observed in subjects with elevated serum hsCRP concentrations (≥3 mg/L) at baseline, suggesting that atorvastatin treatment, especially at the 80 mg dose, may be particularly effective in high risk subjects with chronic low-grade inflammation.

These results support the concept that the beneficial effects of statins may be mediated, in part, by anti-inflammatory effects. HsCRP is an independent risk factor for atherosclerotic disease [1,2,10–12]. Large randomized trials have demonstrated that statins significantly reduce the risk of MI and cardiovascular mortality [27–31], with a magnitude that is greater than expected based on LDL-C reduction alone. In addition, meta-analyses suggest that statins may reduce the risk of stroke to a greater extent than expected based on cholesterol lowering, and more than non-statin lipid lowering therapy [32–34]. This suggests that other factors, such as statin-induced hsCRP reduction, may have a role to play in reducing cardiovascular events.

In this study, 12 weeks of atorvastatin 80 mg therapy was associated with 34% and 24% (SF and ST, respectively) reductions in hsCRP levels, which were greater than those observed in studies with other statins [15,19,21,22,35–39]. Intensive dosing of atorvastatin helps to attenuate the inflammatory response present in high-risk patients [18,40]. Because the circulating levels of inflammatory markers are closely linked to cardiovascular outcomes, these results may explain the incremental beneficial effects of atorvastatin over less potent statins. This is supported by the REVERSAL trial [22], where intensive therapy with atorvastatin 80 mg slowed the progression of atherosclerosis more than moderate therapy with pravastatin40 mg, and after adjustment for the reduction in lipid levels, the decrease in hsCRP levels was independently and significantly correlated with the rate of disease progression [22].
In ACTFAST, high-dose atorvastatin (80 mg) was associated with greater reductions in serum hsCRP levels than lower doses. Other studies in patients with stable coronary disease, acute coronary syndromes, or diabetes have also reported greater reductions in hsCRP levels with higher compared to lower doses of statins [16,38-40]. However, even the lowest dose, atorvastatin 10 mg was associated with significant reductions in hsCRP levels (SF group 18% (6 weeks) and 21% (12 weeks)). This is consistent with studies in patients with acute coronary syndromes [17], and hyperlipidemia [15,41]. Considering that dose groups were of unequal size, the study may have lacked power to find a difference between individual dosing groups, especially for the smallest one (e.g. 40 mg). However, when testing across the whole dose range, a significant dose-response relationship was evident.

In our study, a further significant decrease in hsCRP levels was observed from 6 to 12 weeks with most doses of atorvastatin in both SF (20, 80 mg) and ST (20, 40 mg) groups. In contrast, the SWiss Intervention Trial for lowering CHolesterol (SWITCH) study showed a significant decrease in hsCRP levels within the first 4 weeks and no further decrease at 12 weeks with atorvastatin 10 mg [42]. However, in the Comparative Atorvastatin Pleiotropic effects (CAP) study, atorvastatin 80 mg provided additional reductions in hsCRP concentrations when administered for 6 months (vs. 5 weeks), whereas a plateau was reached after 5 weeks with the 10 mg dose [18]. This suggests that optimum benefits of the highest dose (80 mg) may be achieved when treatment is continued for at least 6 months.

In the overall group, the percentage of patients with hsCRP ≥3 mg/L was relatively large (about 46%) compared with other populations [16]. We observed significant reductions in hsCRP levels at all doses in subjects with baseline hsCRP levels ≥3 mg/L, but only with the 80 mg dose in subjects with hsCRP levels <3 mg/L. This suggests that a significant inhibitory effect of atorvastatin treatment takes place when high levels of inflammatory markers are present, but that high dose therapy may decrease inflammation, regardless of baseline level. This is consistent with previous results obtained with atorvastatin and other statins [17,19,42].

In ACTFAST, there were significant additional reductions of serum hsCRP levels in ST subjects over what was achieved with the previous statin used at baseline. This was most evident in subjects with high hsCRP levels (≥3 mg/L), emphasizing the capacity of higher starting doses of atorvastatin to reduce the inflammatory state in subjects in whom LDL-C levels remained above target despite the use of another statin.

Significant reductions in hsCRP were seen regardless of the presence of diabetes or metabolic syndrome. Significant reduction of hsCRP with pravastatin 40 mg have been shown to be independent of diabetes, cardiovascular disease, smoking, aspirin use, hormone replacement therapy (HRT) use, and lipid levels [19,43]. SF patients with diabetes experienced reductions in hsCRP of 20% and 37% with atorvastatin 10 and 80 mg, respectively. This was similar to results of the Diabetes Atorvastatin Lipid Intervention (DALI) study [16], in which 197 patients with type 2 diabetes experienced reductions in hsCRP levels of 14.6% and 46.7% with 10 mg or 80 mg of atorvastatin.

As shown in other studies [2,19,21,44,45], the statin-mediated changes in hsCRP in ACTFAST were independent of LDL-C or total cholesterol changes. This strongly suggests that the statin-mediated reduction in hsCRP is unlikely to be a consequence of the reduction in LDL-C alone but, rather, is potentially mediated by independent pathways.

Limitations of our study must be considered: the trial was not blinded and the dosing groups (especially the 40 mg) were of unequal sizes. The study lacked a control group, due to ethical considerations. However, it is unlikely that reduction of hsCRP was due to chance or to the improvement of disease, since CHD is a chronic progressive disease and more than 68% of patients displayed a decrease in hsCRP compared to baseline. A single hsCRP sample was taken at each time point while the mean of two samples taken 2 weeks apart would have been preferable to account for variability in measurements [46]. Also, this study was not designed nor powered to investigate the impact of lowering hsCRP concentrations on the incidence of cardiovascular events, especially considering its short (12 weeks) follow-up period. Despite all the evidence behind the use of hsCRP for CHD risk stratification, studies are ongoing to determine if hsCRP should be used to guide therapy and what patient populations are most likely to benefit.

5. Conclusions

Elevated serum hsCRP concentrations provide a useful marker for cardiovascular risk which, when combined with traditional risk factors, may help improve global risk prediction. The reduction in hsCRP levels with statin therapy may explain the clinical benefits of statins, an effect that was shown to be independent of LDL-C and TC lowering in ACTFAST. In addition to effective LDL-C reduction, selecting a starting dose of atorvastatin tailored according to the required level of LDL-C reduction and status of statin use at baseline can help subjects at high risk achieve significant reduction of hsCRP concentrations. In ST subjects, such a regimen provided additional 18–24% reductions in hsCRP over what was attained with the current statin used at baseline. Our data provide strong evidence supporting the anti-inflammatory effects of atorvastatin, particularly the 80 mg dose. This effect is evident as early as 6 weeks and further supports the practice of introducing higher doses of atorvastatin early in the management of patients at high risk for coronary artery disease.
Acknowledgements

The authors of this manuscript have certified that they comply with the Principles of Ethical Publishing in the International Journal of Cardiology [47].

References


